gms | German Medical Science

Purpose: First results of efficacy and side effects after Ozurdex implantation in retinal vein occlusion.

Methods: 38 patients with branch or central retinal vein occlusion were treated with Ozurdex implantation from November 2010 till March 2011. Visual acuity, IOP and SD-OCT were measured monthly.

Results: 38 patients with retinal vein occlusion were treated with Ozurdex. The occlusion happened 1 to 36 months before. 9 patients were pretreated with Avastin. Before Ozurdex implantation mean visual acuity was 0.23 (hand movement to 0.9), mean IOP was 15.9 mmHg and mean central retinal was 592.6 µm (292–1269 µm). At baseline 11 patients were treated with antiglaucomatous therapy. No patient suffered from post operative leakage. The one month control was performed in 23 patients in whom mean visual acuity was 0.29 (0.029–0.6) and mean IOP was 18.86 mmHg (11–40 mmHg). One IOP decomensation to 38 mmHg was seen after implantation in a PEX patient and two more to 38 and 40 mmHg were seen 4 and 8 weeks after implantation. Mean central retinal thickness was 321.63 µm (191–882 µm). Five patients reached the two months control with a mean visual acuity of 0.48 (0.2–0.7), a mean IOP of 19.16 mmHg (12–27 mmHg) and a mean central retinal thickness of 289.38 µm (249–349 µm).

Conclusions: The first results of Ozurdex showed a good efficacy in patients with retinal vein occlusions. Further monthly visits will reveal the time of efficacy, IOP development and visual prognosis.